Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12612001272886
Ethics application status
Approved
Date submitted
11/11/2012
Date registered
7/12/2012
Date last updated
10/01/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparison of oral antidiabetic drugs with insulin in the treatment of Gestational Diabetes Mellitus.
Scientific title
A phase three open label Randomized Controlled Trial to compare the efficacy of oral anti-diabetic drugs with insulin in the treatment of GDM
Secondary ID [1] 281593 0
Nil
Universal Trial Number (UTN)
U1111-1136-5177
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Gestational Diabetes Mellitus 287732 0
Condition category
Condition code
Reproductive Health and Childbirth 288074 288074 0 0
Fetal medicine and complications of pregnancy
Metabolic and Endocrine 288240 288240 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Metformin: Women with fasting blood sugar 95-109 mg/dl will be started on 250mg per oral twice daily and women with fasting blood sugar 110 - 125 mg/dl will be started on 500mg per oral twice daily, half to one hour before meal, which will be increased to achieve glycemic targets (i.e. fasting blood sugar <95mg/dl and post meal blood sugar <120 mg/dl) to a maximum dose 850mg thrice daily.

Glibenclamide: If glycemic control is not achieved on Metformin alone, Glibenclamide 2.5mg per oral per day will be added and increased till a maximum dose of 20mg per day as required.
Intervention code [1] 286160 0
Treatment: Drugs
Comparator / control treatment
Short acting (regular) Insullin will be injected subcutaneously 15-30 minutes pre breakfast, pre lunch and pre dinner and Intermediate-acting insulin will be injected subcutaneously at bedtime. Dose will be calculated according to body weight.

If only Fasting Blood Sugar (FBS) is high, then only bed time Intermediate-acting insulin will be started at a dose of 0.1 - 0.2 units/kg.

If only one or two post prandials are high, then regular insulin at a dose of 0.1 - 0.15 units/kg will be started before a particular meal.

If all the values are high, then basal bolus insulin will be started as Intermediate-acting insullin 0.1 - 0.2 units/kg at bed time and regular insulin 0.1 - 0.15 units/kg before each meal.

Treatment will be continued till delivery.
Control group
Active

Outcomes
Primary outcome [1] 288278 0
As per standard care women did self monitoring of blood glucose (SMBG) and maintained record of SMBG. This data was recorded on excel files. The outcome was assessed from determining average fasting blood glucose (FBG) and average post meal blood glucose recorded in excel files, for (a) 15 days prior to delivery (b) from recruitment to delivery. Following criteria was used for judgement of glycemic control: Excellent control - FBG < 95 mg/dl, Post Prandial < 120 mg/dl Satisfactory control - FBG 95 - 110 mg/dl, Post Prandial 120 - 140 mg/dl. Uncontrolled - FBG > 110 mg/dl, Post Prandial > 140 mg/dl.
Timepoint [1] 288278 0
At the time of admission in the hospital for child birth average blood sugars over 15 days prior to delivery will be calculated from the SMBG chart, as mentioned above.
Secondary outcome [1] 299743 0
Acceptability to treatment will be assessed on structured questionairre.
Timepoint [1] 299743 0
Before discharge of the subject from hospitalization for child birth.
Secondary outcome [2] 300144 0
Cost of treatment. The clinical trial unit pharmacy of Aga Khan University will maintain drug log for each subject. The pharmacy will calculate the cost from this log.
Timepoint [2] 300144 0
Cost will be calculated at the end of study period of that particular subject.

Eligibility
Key inclusion criteria
Women diagnosed as GDM, according to criteria given in the protocol.

Singleton pregnancy.

Women who consented for study.
Minimum age
18 Years
Maximum age
40 Years
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
Pre-gestational type 1 and type 2 diabetes mellitus
Overt diabetes (FBG > or equal to 126 mg/dl, Hb A1C > or equal to 6.5%)
Gestational age > 33 weeks at the time of recruitment.
Patients on steroid therapy
Women not tolerating Oral Glucose Tolerance Test.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
A sealed opaque envelope
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Block Randomization
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
17/12/2012
Actual
18/01/2013
Date of last participant enrolment
Anticipated
Actual
9/05/2014
Date of last data collection
Anticipated
Actual
14/11/2014
Sample size
Target
154
Accrual to date
Final
154
Recruitment outside Australia
Country [1] 4660 0
Pakistan
State/province [1] 4660 0
Sindh

Funding & Sponsors
Funding source category [1] 286239 0
University
Name [1] 286239 0
Aga Khan University
Country [1] 286239 0
Pakistan
Primary sponsor type
Individual
Name
Dr Aisha Syed Wali
Address
Department of Obstetrics and Gynaecology
Aga Khan University Hospital Stadium Road,
P.O. Box 3500,
Postcode 74800,
Karachi.
Country
Pakistan
Secondary sponsor category [1] 285046 0
None
Name [1] 285046 0
Address [1] 285046 0
Country [1] 285046 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 288319 0
Ethica Review Committee, Aga Khan University
Ethics committee address [1] 288319 0
Ethics committee country [1] 288319 0
Pakistan
Date submitted for ethics approval [1] 288319 0
Approval date [1] 288319 0
22/12/2010
Ethics approval number [1] 288319 0
1681-Obs-ERC-2010.

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 34896 0
Dr Aisha Syed Wali
Address 34896 0
Department of Obstetrics & Gynecology, The Indus Hospital, Korangi Crossing, Postcode.75190 Karachi, Pakistan.
Country 34896 0
Pakistan
Phone 34896 0
+92 300 2510261
Fax 34896 0
Email 34896 0
aisha.wali@tih.org.pk
Contact person for public queries
Name 18143 0
Aisha Sheikh
Address 18143 0
Department of Medicine
Aga Khan University Hospital
Stadium Road,
P.O. Box 3500,
Postcode 74800,
Karachi.
Country 18143 0
Pakistan
Phone 18143 0
+92 21 34864448
Fax 18143 0
Email 18143 0
aisha.sheikh@aku.edu
Contact person for scientific queries
Name 9071 0
Aisha Syed Wali
Address 9071 0
Department of Obstetrics & Gynecology, The Indus Hospital, Korangi Crossing, Postcode.75190 Karachi, Pakistan.
Country 9071 0
Pakistan
Phone 9071 0
+92 300 2510261
Fax 9071 0
Email 9071 0
aisha.wali@tih.org.pk

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
TypeIs Peer Reviewed?DOICitations or Other DetailsAttachment
Basic resultsNo 363218-(Uploaded-19-01-2021-04-53-57)-Basic results summary.docx

Documents added automatically
No additional documents have been identified.